What Hypera Pharma does

Hypera Pharma (B3: HYPE3) is Brazil's largest pharmaceutical company, founded in 2001 and headquartered in São Paulo with 10,000+ employees. The company operates a horizontally diversified portfolio across five business units: Consumer Health OTC (iconic brands including Benegrip, Buscopan, Engov, Estomazil, Neosaldina, Zero-Cal, Vitasay), Prescription drugs via Mantecorp Farmasa (Addera D3, Alivium, Predsim, Rinosoro), Generics and Similars via Neo Química (400+ SKUs present in 99% of Brazilian pharmacies), Dermocosmetics (Mantecorp Skincare, Simple Organic, Bioage with proprietary neurocosmetics/prebiotic technology), and Institutional supply to clinics and hospitals.

The company monetizes primarily through unit-pricing on physical-pharmacy distribution (Neo Química), complemented by a 1,000+-strong Mantecorp Farmasa medical-representative detailing network for prescription products, and direct-to-consumer e-commerce through iHypera and brand-specific storefronts. Pricing strategy spans premium OTC brands down to generics priced approximately 60% below reference drugs. Manufacturing is anchored at Anápolis and Goiânia production facilities, with active R&D funded in part by a R$363.8 million BNDES loan supporting oncology drug development and Neolyte electrolyte-replacement formulation launches in 2024-2025.

Distribution and brand reach constitute the core commercial engine: Neo Química's 99% pharmacy penetration, multi-decade brand equity (Neosaldina 50+ years, Neo Química 65+ years), and heavy consumer marketing (ranked 2nd largest digital advertiser in Brazil Q1 2025) drive volume across consumer and pharmacy channels. Recent strategic priorities include defense against the EMS hostile takeover (countered via a Votorantim-led R$1.5 billion capital raise, Feb 2026), pending ANVISA/CMED review of Semavy (semaglutide pen for the R$5.7 billion Brazilian GLP-1 market), and exploration of Sanofi's Medley brand acquisition.

Name

Hypera Pharma

Legal name

HYPERA S.A.

Website

https://hypera.com.br

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Hypera Pharma is Brazil's largest pharmaceutical company, selling OTC, prescription, generic, and dermocosmetic products through 99% pharmacy reach, a 1,000+ medical-rep network, and e-commerce, serving mass-market consumers, physicians, and healthcare institutions.

Ownership category

akta.pro rank

Product category

Pharmaceutical Products

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

Keywords

• Pharmaceutical products
• Over-the-counter medications
• Generic medications
• Prescription drugs
• Dermocosmetics

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Consumer Health Products: Sale of over-the-counter medications including Benegrip, Buscopan, Engov, Epocler, Estomazil, Neosaldina, Zero-Cal, and Vitasay vitamins and supplements. This is the company's largest segment where they hold market leadership position in Brazil.
2. Prescription Products (Mantecorp Farmasa): Sale of prescription medications through a network of over 1,000 medical representatives across Brazil, with brands including Addera D3, Predsim, Maxsulid, Celestamine, Alivium, Rinosoro, and others targeting primary care therapeutic areas.
3. Generics and Similar Products (Neo Química): Sale of generic and similar medications with portfolio of 400+ products, present in 99% of Brazilian pharmacies. Neo Química is the leader in units sold in Brazil's generic market.
4. Dermocosmetics (Mantecorp Skincare, Simple Organic, Bioage): Sale of skincare and dermocosmetic products through retail pharmacies and e-commerce platforms targeting dermatological care needs.
5. Institutional Market: Products and services targeted at clinics and hospitals, representing a newer strategic expansion for the company.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Hypera Pharma is Brazil's largest pharmaceutical company, developing, manufacturing, and selling a diversified portfolio of healthcare products across OTC consumer health (Benegrip, Buscopan, Engov, Neosaldina, Estomazil, Vitasay, Zero-Cal), prescription drugs via Mantecorp Farmasa (Addera D3, Alivium, Predsim), generic and similar medications via Neo Química (400+ products in 99% of Brazilian pharmacies), and dermocosmetics via Mantecorp Skincare, Simple Organic, and Bioage. The company also serves an institutional market for clinics and hospitals and is developing semaglutide-based weight-loss products (Semavy).

Product overview

Hypera Pharma operates as a diversified pharmaceutical company with a multi-segment portfolio organized into distinct business units: Consumer Health (OTC medications including Benegrip, Buscopan, Engov, Neosaldina, Estomazil, Epocler, Zero-Cal, Vitasay, Apracur, Gelol), Prescription Products via Mantecorp Farmasa (Addera D3, Alivium, Predsim, Maxsulid, Celestamine, Rinosoro, Descon), Dermocosmetics via Mantecorp Skincare, Simple Organic, and Bioage, Generics and Similars via Neo Química (400+ products), and Institutional Market for clinics and hospitals. The company positions itself as Brazil's largest pharmaceutical company with leadership across multiple categories.

Differentiator

Problem solved

Functional benefit

Brands

• Benegrip: Leading brand for flu and cold treatment in Brazil, with complete product line including traditional Benegrip, Benegrip Imuno, Benegrip Multi Dia and Noite, Benetosse syrup, and children's line.
• Buscopan
• Engov
• Epocler
• Estomazil
• Neosaldina
• Zero-Cal
• Addera
• Vitasay
• Apracur
• Alivium
• Gelol
• LactoPurga
• Maracugina
• Merthiolate
• Nebacetin
• Polaramine
• Tamarine
• Biotonico Fontoura

Products and services

• Consumer Health (OTC) Portfolio Over-the-counter medications, supplements, and self-care products marketed under iconic Brazilian brands (Benegrip, Buscopan, Engov, Neosaldina, Estomazil, Vitasay, Zero-Cal, Apracur, Gelol) for treatment of common ailments including flu, cold, headache, heartburn, digestive issues, and nutritional supplementation. Targeted at Brazilian consumers through pharmacy retail channels.
• Mantecorp Farmasa Prescription Drugs Prescription medications marketed under Mantecorp Farmasa including Addera D3, Predsim, Maxsulid, Celestamine, Alivium, Rinosoro, Descon, Lisador, Ofolato, Colflex, and Mioflex for primary care therapeutic areas. Distributed through 1,000+ medical representatives to physicians and pharmacies across Brazil.
• Neo Química Generics and Similars Generic and similar medications under Neo Química brand with 400+ products covering cardiovascular, central nervous system, allergies, pain, and fever categories. Present in 99% of Brazilian pharmacies (IQVIA Retail Insights MAT Nov'24), priced approximately 60% below reference brands. Targeted at cost-conscious Brazilian consumers and chronic disease patients.
• Mantecorp Skincare Dermocosmetics Dermocosmetics and skincare products with over 40 years in dermatological market, including Episol (sunscreen), Blancy TX (spot corrector), Hydraporin AI (cleansing oil), Epidrat Hyalu (lip oil). Distributed through retail pharmacies, e-commerce platforms, and targeted at dermatological and beauty care consumers.
• Simple Organic Dermocosmetics Dermocosmetics brand acquired and integrated within Hypera's skincare portfolio, sold through brand e-commerce platform simpleorganic.com.br.
• Bioage Dermocosmetics Dermocosmetics brand with proprietary neurocosmetics and prebiotic technology. Includes Bio.Clean System PRO professional skin cleaning line for dermatological care. Sold through Bioage e-commerce platform and retail channels.
• Institutional Market Products Products and services targeted at healthcare institutions including clinics and hospitals, representing a newer strategic B2B expansion focused on institutional procurement, bulk medication supply, and clinical care support.
• Neolyte Electrolyte Replacer Oral rehydration solution launched by Neo Química in July 2025 for treatment of dehydration from diarrhea, vomiting, viruses, dengue, and excessive sweating. Available in liquid (500ml) and powder sachets (4 units per box) in multiple flavors. Targeted at general consumers.
• Semavy (Semaglutide Pen) Semaglutide-based pen product for diabetes management and weight loss, pending regulatory approval. Targets the Brazilian weight-loss injection market.
• Buscofem Girls (Menstrual Pain) Feminine health product targeting Gen Z demographic for menstrual pain relief under the Buscofem brand.

Quantifiable outcome

• 60% cost savings with generic medications versus reference brands
• +4 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Six partnerships are on record, tiered minor and core.

• EMSminorOthers · 4 May 2026EMS, a major Brazilian pharmaceutical company, attempted a hostile takeover bid for Hypera Pharma but withdrew after just seven days in late October 2024. Withdrawal driven by Hypera shareholder João Alves de Queiroz Filho's rapid stock purchases and buybacks countering EMS's approach.
• Léo SantanaminorGTM or Marketing Partner · 10 January 2025Singer Léo Santana became brand partner and co-owner of Engov After Pink Lemonade flavor, participating in Baile da Santinha 2025 event activations, promotional campaigns, and advertising throughout Carnival season.
• ParamountminorGTM or Marketing Partner · 26 July 2024Benegrip announced partnership with Paramount to expand its children's care product line, leveraging entertainment brand association for marketing activations targeting families.
• Semaglutide Patent HoldersminorOthersCompanies including Hypera, Biomm, EMS, and Eurofarma preparing for patent expiration of semaglutide in March, expected to reduce costs by approximately 70% and open market to generic versions of GLP-1 weight-loss medications.
• Sanofi (Potential Acquisition Target)minorStrategic or Co-development PartnerHypera exploring potential acquisition of Sanofi's Medley brand as part of strategic portfolio expansion amid M&A activity in Brazilian pharmaceutical sector where multinationals including Sanofi are divesting local operations.
• B3 (Brazilian Stock Exchange)coreOthersHypera Pharma follows B3's Novo Mercado highest governance standard, is included in IDIVERSA diversity index, ICO2 carbon efficiency index, and reports under GRI, SASB, and TCFD frameworks for sustainable business practices.

Scale indicators14 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Eurofarma Laboratórios: Large Brazilian pharmaceutical company operating across prescription, generics, OTC, hospital and animal health. Competes head-to-head with Hypera in the upcoming post-patent semaglutide pens race and ranks among the leading Brazilian generics players.
• EMS Pharma: Brazil's other leading domestic pharmaceutical manufacturer spanning generics, branded Rx, OTC and hospital lines. Attempted a hostile takeover of Hypera in Oct 2024 and is simultaneously co-developing semaglutide pens with Hypera/Biomm/Eurofarma, making it Hypera's closest direct competitor in every segment.
• Medley (Sanofi): Sanofi-owned Brazilian generics business that Hypera is publicly evaluating as a potential acquisition target. Operates as a direct competitor in the Brazilian generics market while also functioning as a strategic counterpart in M&A scenario analysis.
• Aché Laboratórios: Brazilian pharmaceutical company with diversified prescription, OTC and generics portfolio, similar diversification strategy to Hypera. Operates a comparable medical-rep-driven prescription model alongside consumer health brands.
• Libbs Farmacêutica: Brazilian pharmaceutical manufacturer with prescription, generics and dermocosmetics portfolio. Operates in similar therapeutic categories as Mantecorp Farmasa and competes in Brazilian women's health and dermatology segments where Hypera's Buscofem and Mantecorp Skincare are established.

Broad incumbents

• GSK Brazil (GlaxoSmithKline): Global pharmaceutical and consumer healthcare major with a Brazil presence that competes with Hypera's OTC and consumer health brands (e.g., analgesics, allergy, cold/flu). Notable for ongoing global consumer healthcare separations that could trigger Brazil-specific divestitures.
• Pfizer Brazil: Multinational pharmaceutical incumbent operating broadly in the Brazilian market across prescription and vaccines. Overlaps with Hypera in primary care, oncology (where Hypera is building capacity) and selected specialty therapeutics, though Pfizer operates as a portfolio player rather than Brazil-pure-play.

Emerging players

• Cristália: Brazilian pharmaceutical company specializing in hospital/institutional and specialty pharmaceutical products. Overlaps directly with Hypera's newer institutional market expansion and oncology build-out plans.
• Biolab Farmacêutica: Mid-sized Brazilian pharmaceutical company with strong prescription and dermatology focus that competes with Hypera's Mantecorp Skincare and Mantecorp Farmasa divisions in dermatology and select Rx categories.
• Biomm: Smaller Brazilian biopharma focused on biologics and partnered on post-patent semaglutide pens with Hypera/EMS/Eurofarma. Direct overlap on the GLP-1 opportunity makes it a relevant emerging peer despite smaller scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtiktok.com/@hypera.pharma
• YouTubeyoutube.com/user/hypermarcasoficial
• LinkedInlinkedin.com/company/hypera
• Instagraminstagram.com/hyperaoficial
• Facebookfacebook.com/200558713824391

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries5 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hypera Pharma